Cargando…
Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors
Claudin18.2 (CLDN18.2) is a tight junction protein that is overexpressed in a variety of solid tumors such as gastrointestinal cancer and oesophageal cancer. It has been identified as a promising target and a potential biomarker to diagnose tumor, evaluate efficacy, and determine patient prognosis....
Autores principales: | Chen, Yan, Hou, Xingguo, Li, Dapeng, Ding, Jin, Liu, Jiayue, Wang, Zilei, Teng, Fei, Li, Hongjun, Zhang, Fan, Gu, Yi, Yu, Steven, Qian, Xueming, Yang, Zhi, Zhu, Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Xi'an Jiaotong University
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173170/ https://www.ncbi.nlm.nih.gov/pubmed/37181294 http://dx.doi.org/10.1016/j.jpha.2023.02.011 |
Ejemplares similares
-
Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”
por: Li, Cuicui, et al.
Publicado: (2023) -
CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023) -
Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
por: Chen, Jinxia, et al.
Publicado: (2023) -
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023) -
CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
por: Wang, Canming, et al.
Publicado: (2023)